Contact information
Research groups
Abhishek Puthenveetil
Postdoctoral Research Assistant in Immuno-Oncology
Decoding immune resistance in tumors
I’m an immunologist exploring how immune cells sense and adapt to their physical and molecular environment within tumors. My scientific path began at MD Anderson Cancer Center in the US, where I worked on CAR T cell engineering and RNA interference pathways through an Indo-US fellowship. I later focused on macrophage polarization during my research internship, studying how signaling and microenvironmental cues drive inflammatory balance.
During my doctoral training in Israel, I investigated how mechanotransduction and calcium signaling orchestrate NK-cell activation and exhaustion. My work revealed that mechanical forces such as tumor stiffness can dynamically tune immune signaling and stratify exhaustion over time, offering new perspectives on how the tumor microenvironment shapes immunity.
At the Kennedy Institute, I am focusing on how tumors exclude cytotoxic lymphocytes over time and investigating the cellular and molecular mechanisms that drive this immune evasion. Outside the lab, I enjoy writing, journaling, and exploring creative ways to connect science with everyday life.
Recent publications
Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies.
Journal article
Puthenveetil A. et al, (2025), Mol Ther Methods Clin Dev, 33
Isolation and characterization of primary NK cells and the enrichment of the KIR2DL1+ population.
Journal article
Sabag B. et al, (2025), Methods Cell Biol, 193, 201 - 211
Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.
Journal article
Sabag B. et al, (2024), EMBO J, 43, 2552 - 2581
ctin Retrograde Flow Regulated by the Wiskott-Aldrich Syndrome Protein Drives the Natural Killer Cell Response.
Journal article
Sabag B. et al, (2022), Cancers (Basel), 14
Inhibition of SHP-1 activity by PKC-θ regulates NK cell activation threshold and cytotoxicity.
Journal article
Ben-Shmuel A. et al, (2022), Elife, 11
Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity.
Journal article
Biber G. et al, (2022), EMBO Mol Med, 14
Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies.
Journal article
Biber G. et al, (2021), Nat Commun, 12